Obstructive Jaundice

Meet the patient

A 68-year-old man is sent by his GP for "going yellow." Three weeks of painless, deepening jaundice, pale floating stools, tea-coloured urine, and a stone of weight loss — no fever, no abdominal pain. The sclerae are icteric and there is a smooth, non-tender, ballotable mass in the right upper quadrant. The question that decides his next 48 hours is the question that decides every obstructive jaundice: is this a stone, a tumour, or pus under pressure?^[1]

Hold a second patient beside him — a 54-year-old woman who arrives shaking with rigors, febrile, jaundiced, and tender in the right upper quadrant, Charcot's triad in a single body. She is the emergency; he is the workup. Both live in this topic, and the difference between them is the difference between a ward bed and an intensive-care bed.^[8]

The biliary tree in ninety seconds

Know the ducts cold — every level of obstruction maps to a cause, and the viva starts here. Bile leaves the hepatocyte through canaliculi, gathers into segmental and area ducts, then the right and left hepatic ducts. The two hepatic ducts join at the porta hepatis to form the common hepatic duct (about 4 cm). The cystic duct from the gallbladder joins it to make the common bile duct (CBD), which runs in the free edge of the lesser omentum, passes behind the first part of the duodenum, and grooves the back of the pancreatic head before meeting the main pancreatic duct of Wirsung at the ampulla of Vater (the hepatopancreatic ampulla). The ampulla opens on the medial wall of the second part of the duodenum at the major papilla, ringed by the sphincter of Oddi (of Boyden), the circular smooth muscle that regulates bile and pancreatic juice flow and stops duodenal reflux.^[1]

The gallbladder sits in its fossa under the liver, stores and concentrates bile 5 to 10 times, and empties on cholecystokinin when fat reaches the duodenum. ASGE high-risk choledocholithiasis includes a dilated common bile duct (>6 mm with the gallbladder in situ) together with a total bilirubin over 4 mg per decilitre — so a dilated duct is a predictor, not a standalone diagnosis.^[1]

Dark urine, pale stools, raised ALP — the cholestatic signature

The single triage decision in any jaundiced patient is medical versus surgical — and the bloods make it for you. Obstructive jaundice is conjugated (direct) hyperbilirubinaemia carrying a cholestatic enzyme pattern: ALP and GGT raised out of proportion to AST and ALT, which stay only mildly deranged unless a transient biliary-obstruction spike intervenes. Marked isolated transaminase elevation points instead toward hepatocellular injury — that is a medical jaundice until imaging proves a stone.^[1]

The bedside fingerprint to recite aloud: dark urine, pale stools, raised ALP, conjugated bilirubin, itchy skin. Scleral icterus is an unreliable screen: at 2.5 mg per decilitre (42.8 micromol per litre) only 58 per cent of examiners detected it, and at 3.1 mg per decilitre (53.0 micromol per litre) 68 per cent did — so trust the bilirubin over the eyeball.^[26]

The classic trap: choledocholithiasis usually raises ALP out of proportion to the transaminases, but a transient AST or ALT spike above 1000 units per litre in acute biliary obstruction is a well-described mimic of viral hepatitis — a meta-analysis puts ALT or AST over 1000 IU per litre at 6 to 9.6 per cent of patients with CBD stones (pooled 7.8 per cent), and a pooled 33.1 per cent exceed 500 IU per litre. The raised ALP, and the dilated duct on ultrasound, rescue you. Read the whole pattern, never the transaminase in isolation.^[17][18]

The three patterns that name the cause

Tempo, pain, and fever separate the three obstructive jaundices before any scan. Place the patient in one of these three boxes and the rest of the workup follows almost on its own.^[1]

Courvoisier's law — the gallbladder that means cancer

In a jaundiced patient, a palpable, non-tender, distended gallbladder is unlikely to be stones. That is Courvoisier's law — Ludwig Georg Courvoisier, the Swiss surgeon, 1890 — and the mechanism is purely mechanical. Repeated bouts of stone-driven chronic cholecystitis scar and contract the gallbladder wall, so a gallbladder ravaged by stones cannot distend. A distended palpable gallbladder therefore implies the lower tree is blocked by something that has never scarred it — classically carcinoma of the pancreatic head, where bile backs up into a pristine, distensible sac.^[1]

The law is statistical, not absolute. Name the exceptions for the viva: a double impaction (a stone at the cystic duct plus another at the ampulla), a pancreatic pseudocyst, and a stone forming de novo in a previously unscarred gallbladder. The mirror-image pearl earns marks: most stone jaundice is painful and the gallbladder is impalpable.^[1]

The classic trap: labelling a Courvoisier-positive gallbladder "gallstones" and discharging the workup. A palpable gallbladder in a jaundiced patient is malignancy until disproved — the very next step is a contrast CT and MRCP, not a clinic review in six weeks.^[1]

Classification by level and mechanism

Classify by where the block sits and what is causing it — anatomy first, mechanism second. Extrahepatic obstruction is the surgical side of the line; intrahepatic causes are mostly medical, but a handful (PSC, PBC, drugs, sepsis) sit on the physician's list, so draw the boundary explicitly.^[1]

^{[1] [4] [1] [4]}

Who gets obstructed, and the bimodal age

The single most discriminating epidemiological fact is the bimodal age of the cause. Under 50, think stones (choledocholithiasis). Over 60, think malignancy — pancreatic head, cholangiocarcinoma, ampullary — and weight loss and painless progression rise with the age band.^[1]

Gallstone risk still rides the 5 Fs — female, forty, fertile, fair, fat — plus rapid weight loss, the oral contraceptive pill, total parenteral nutrition, ileal Crohn's disease, and haemolytic anaemia (pigment stones). Pancreatic head cancer is associated with smoking, long-standing type 2 diabetes, chronic pancreatitis, familial cancer syndromes (BRCA2, Peutz-Jeghers, Lynch, hereditary pancreatitis), and obesity. Cholangiocarcinoma clusters in primary sclerosing cholangitis, liver-fluke infestation (Clonorchis, Opisthorchis in South-East Asia — praziquantel decreases that risk, though reinfection is common), choledochal cysts, and hepatolithiasis (recurrent pyogenic cholangitis).^[4][13]

The pathophysiology cascade

Whatever the level, obstruction produces the same recognisable cascade — trace what happens when conjugated bilirubin and bile salts cannot reach the gut.^[1]

1. Bile cannot reach the duodenum. Conjugated bilirubin, normally excreted in bile and converted to urobilinogen then stercobilin by gut bacteria (the brown of stool), now backs up. Rising intrabiliary pressure ruptures hepatocyte tight junctions; conjugated bilirubin regurgitates straight into plasma and, being water-soluble, is filtered at the glomerulus — the patient's dark brown urine. The lost stercobilin turns the stool pale and clay-coloured, the patient often volunteering that it is "putty-like" or floats (steatorrhoea).^[1]
2. Bile salts accumulate in plasma and deposit in skin — the cause of pruritus, characteristically worse at night, affecting palms and soles, partly central (opioid-receptor mediated) and partly peripheral (TGR5 receptor on sensory neurones). Scratch marks and excoriations may be the most striking physical sign.^[1]
3. Fat maldigestion and malabsorption. With no bile in the gut, dietary triglyceride cannot be emulsified into micelles — steatorrhoea ensues, and the fat-soluble vitamins A, D, E, and K are malabsorbed. Vitamin K deficiency is the most acute consequence: the vitamin-K-dependent factors II, VII, IX, and X fall and the prothrombin time prolongs within one to two weeks of complete obstruction. This is reversible with parenteral vitamin K — the discriminator from the irreversible coagulopathy of hepatocellular failure. Chronic cholestasis eventually brings osteomalacia and hepatic osteodystrophy.^[1]
4. Biliary stasis predisposes to ascending infection. Bile is normally sterile, but obstruction raises intraductal pressure, disrupts the bile-canaliculus barrier, and lets gut organisms — classically Escherichia coli, Klebsiella, Enterococcus, and anaerobes — ascend from the duodenum or enter via the portal vein. Infected bile under pressure spills into the systemic circulation (cholangio-venous reflux), producing the bacteraemia, rigors, and septic shock of ascending cholangitis.^[8]
5. Progressive hepatocellular dysfunction. Unrelieved obstruction causes secondary biliary cirrhosis within months — the reason to relieve even a malignant obstruction when the cancer itself is incurable.^[1]

At the bedside — signs that move the working diagnosis

Examination rarely delivers a single diagnostic sign; its job is to place the patient in one of the three boxes and find the danger signs. Look first for stigmata of chronic liver disease — palmar erythema, spider naevi, gynaecomastia, caput medusae, asterixis — their presence argues for a hepatic, not surgical, cause. Feel for Virchow's node in the left supraclavicular fossa (Troisier's sign) — metastatic abdominal malignancy, typically gastric or pancreatic, until proven otherwise.^[1]

The abdominal sweep: surgical scars (prior cholecystectomy raises a retained stone or a stricture), cachexia, a palpable non-tender gallbladder (Courvoisier-positive — malignancy), a hard irregular liver edge (metastases or hepatocellular carcinoma), a craggy fixed RUQ mass (gallbladder carcinoma), an epigastric mass or Sister Mary Joseph nodule at the umbilicus (advanced pancreatic cancer), and ascites (peritoneal metastases or decompensated cirrhosis). An upper abdominal bruit occasionally betrays a vascular pancreatic tumour; a succussion splash suggests gastric outlet obstruction from a periampullary mass.^[1]

Constitutional clues worth naming: scratch marks are the sign of pruritus, not jaundice itself; cachexia whispers malignancy; bruising flags the coagulopathy you must correct before any procedure. Take a focussed history — pale floating stools and dark urine, travel, transfusion, drugs (flucloxacillin, co-amoxiclav, anabolic steroids, the oral contraceptive), alcohol, sexual exposure, family cancer history, and the weight-loss trajectory.^[1]

Named signs worth knowing for the viva

Differential — three categories, one blood pattern

The first fork is pre-hepatic, hepatic, or post-hepatic — the bloods draw the line, imaging narrows it.^[1]

^[1]

The GGT parallels ALP in biliary disease and confirms the biliary origin of a raised ALP — an isolated high ALP of bone origin keeps a normal GGT. The prothrombin time prolongs in cholestasis from vitamin K malabsorption and corrects with parenteral vitamin K, a useful bedside discriminator from the irreversible coagulopathy of hepatocellular failure.^[1]

The diagnostic ladder — ultrasound first, MRCP gold, ERCP therapeutic

Imaging answers two questions in sequence: is the tree dilated, and where and what is the block? The ladder runs non-invasive to invasive, diagnostic to therapeutic — never reach for ERCP before MRCP unless you intend to treat.^[1][3]

Bloods first

^[1]

The core panel: conjugated bilirubin raised, ALP and GGT raised out of proportion to AST and ALT (which stay low unless the transient cholangitic-hepatitis spike intervenes). PT and INR may be prolonged because cholestasis depletes fat-soluble vitamin K — supplementation corrects it, so check coagulation before any biliary instrumentation.^[17][27]

Tumour markers — two named traps. CA 19-9 is the best-validated serum marker for symptomatic pancreatic cancer, but Scarà notes false-negative results in Lewis (a-b-) genotype, false-positive elevation in benign disease, and a positive predictive value of only 72.3 per cent — so it is not a cancer-specific screen. It also rises in benign biliary obstruction and cholangitis. CEA may support cholangiocarcinoma; alpha-fetoprotein excludes hepatocellular carcinoma in the cirrhotic; IgM anti-mitochondrial antibody confirms PBC. Add viral and autoimmune screens if a hepatocellular cause is plausible (hepatitis B surface antigen, hepatitis C antibody, hepatitis A and E IgM, anti-smooth muscle, anti-nuclear, anti-LKM antibodies).^[1]

The imaging ladder

^{[1] [3]}

Diagnostic accuracy at a glance

The meta-analysis by Garrow and colleagues (2007) reported endoscopic ultrasound sensitivity 89 per cent and specificity 94 per cent for choledocholithiasis (overall biliary-obstruction sensitivity 88 per cent, specificity 90 per cent). A later ASGE pooled comparison found EUS more sensitive than MRCP (0.97 versus 0.87) with no specificity difference.^[3]

The cholangitis emergency — pus under pressure

Acute ascending cholangitis is the surgical emergency of biliary obstruction: infected bile under pressure spilling organisms into the circulation. There is no levity in this section, and no time to waste. The Tokyo Guidelines 2018 (TG18) frame the diagnosis, the severity, and the bundle.^[8][9]

Charcot's triad — Jean-Martin Charcot, the French neurologist, 1877 — is fever, jaundice, and right-upper-quadrant pain. The full triad is insensitive as a stand-alone screen, so an obstructed, febrile patient is cholangitis until disproved. Reynolds' pentad (1959) adds hypotension and altered mental state and maps onto the highest TG18 severity band (organ dysfunction). TG18 validation showed 30-day mortality rises significantly with each step up in severity grade; the surgical dictum is pus under pressure needs decompression.^[8][10]

The bundle below is the opening move in every cholangitis patient — cultures and antibiotics drawn before the ERCP, not after.^[10]

^{[8] [9] [10]}

Definitive treatment is biliary drainage — antibiotics alone will not cure an obstructed, infected system. TG18 validation found no 30-day mortality difference from early or urgent drainage in Grade I or Grade III, but significantly lower 30-day mortality in Grade II drained early or urgently. In refractory shock, drain as soon as the patient can be moved to the suite. Percutaneous transhepatic or surgical drainage are second line when ERCP fails or is unavailable.^[8][10]

Tokyo Guidelines 2018 severity grading

^{[8] [9]}

Correct the clotting before you cut — vitamin K and the rest

Weeks of obstruction starve the gut of bile — and bile is what carries fat-soluble vitamins across it. Cholestasis carries a well-recognised risk of fat-soluble vitamin deficiency, including vitamin K, and K deficiency means coagulopathy; a scoping review of cholestatic patients found supplementation routine practice even though dosing regimens are not uniformly validated. So check the PT/INR in every obstructed patient and correct the deficiency before any instrument crosses the papilla.^[27]

Pruritus in cholestasis can be a major burden that dramatically impairs quality of life. Candidate pruritogens include lysophospholipids and sulfated progesterone metabolites; total bile acid or bilirubin conjugates seem unlikely to dominate. Treat the itch — do not shrug at it.^[24]

Nutrition and analgesia: a low-fat diet, oral fat-soluble vitamins A, D, E, K, and pancreatic enzyme replacement if the pancreas is insufficient (chronic pancreatitis, post-Whipple). Pain control while the duct is still obstructed should follow local analgesic policy; this topic does not carry a sourced Oddi-tone comparison between opioids.^[1]

Choledocholithiasis — the ASGE three risk tiers

Before any ERCP, stratify the probability of a CBD stone — the ASGE 2019 guideline systematically reviewed the clinical predictors of choledocholithiasis and the diagnostic choice between EUS and MRCP, because ERCP is the primary treatment but carries adverse events in 6 to 15 per cent.^[6]

^[6]

Definitive therapy is ERCP with endoscopic sphincterotomy and stone extraction using a balloon or Dormia basket. ASGE flags large (>10 mm) stones as potentially difficult to remove, alongside unusual hardness or an abnormal distal duct. After clearance, laparoscopic cholecystectomy during the same admission prevents recurrent stone migration. In young, fit patients, single-stage laparoscopic CBD exploration at cholecystectomy is an alternative where ERCP is unavailable.^[6][7]

Pancreatic head cancer — Whipple, adjuvant chemo, and what to stent

Most pancreatic head cancers are not resectable at presentation — locally advanced or metastatic disease is the usual finding, and the jaundice is often the symptom that brings them in.^[1]

^[1]

Curative intent is the Whipple (pancreaticoduodenectomy) when the tumour is resectable: no distant metastases, no encasement of the superior mesenteric artery or coeliac axis, and no unreconstructable superior mesenteric or portal vein involvement. The classical Whipple removes the head of the pancreas, the second and third parts of the duodenum, the distal common bile duct, the gallbladder, and the distal stomach; the contemporary standard spares the pylorus (pylorus-preserving pancreaticoduodenectomy). Reconstruction is by pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy (or duodenojejunostomy).^[1]

The dominant morbidities after Whipple are post-operative pancreatic fistula, delayed gastric emptying, and post-pancreatectomy haemorrhage. Minimally invasive (laparoscopic or robotic) Whipple is increasingly performed in selected centres: the 2025 DIPLOMA-2 randomised trial showed MIPD non-inferior to open surgery for 90-day overall complications (mean Comprehensive Complication Index 33.4 versus 35.3).^[16]

Adjuvant chemotherapy with gemcitabine plus capecitabine (ESPAC-4: median overall survival 28.0 versus 25.5 months for gemcitabine alone; HR 0.82) is the regimen that trial named as the new standard after resection. For metastatic disease in fit patients, FOLFIRINOX (PRODIGE 4/ACCORD 11) improved median overall survival to 11.1 versus 6.8 months with gemcitabine, at the cost of more toxicity including 5.4 per cent febrile neutropenia.^[11][12]

Palliation in unresectable extrahepatic malignant obstruction: ESGE recommends SEMS insertion for palliative drainage, and against uncovered SEMS when the etiology is unconfirmed. For malignant hilar obstruction, ESGE recommends uncovered SEMSs. If duodenal obstruction develops, endoscopic duodenal stenting or surgical gastric bypass and a coeliac plexus block for refractory pain are the usual adjuncts — those adjunct rates are not sourced here.^[7]

^{[12] [11] [16]}

Preoperative biliary drainage — the controversy that isn't

Routine preoperative biliary drainage before Whipple was meant to help — the Dutch trial proved it harms. van der Gaag et al. (NEJM 2010) randomised patients with resectable pancreatic head cancer and bilirubin 40 to 250 micromol per litre to immediate surgery versus PBD then surgery: among 202 enrolled (96 early surgery, 106 PBD; 6 excluded from analysis) PBD significantly increased serious complications (74 per cent versus 39 per cent) with no significant difference in surgery-related complications. PBD is now reserved for cholangitis, severe symptomatic jaundice (intense pruritus), delayed surgery, or neoadjuvant chemotherapy — matching ESGE 2018.^[5]

^[5]

Cholangiocarcinoma and Klatskin — location decides the operation

Approach and prognosis hinge on where along the biliary epithelium the tumour sits. The perihilar tumour carries Gerald Klatskin's name — Klatskin, the American hepatologist who characterised the bifurcation tumour in 1965; "Klatskin tumour" and "hilar cholangiocarcinoma" are the same lesion, sorted by the Bismuth-Corlette types according to how far up the confluence the tumour climbs.^[13][14]

• Distal cholangiocarcinoma — Whipple if resectable; Brindley cites post-resection survival ranging from 20 to 40 per cent depending on disease extent.^[13]
• Perihilar (Klatskin) — the AHPBA consensus: ideal treatment is resection of the intra- and extrahepatic bile ducts plus the involved ipsilateral liver. Pre-operative portal vein embolisation is a safe strategy when the future liver remnant is under 30 per cent. Pathologic confirmation is not required before resection.^[14]
• Intrahepatic cholangiocarcinoma — anatomical hepatic resection; adjuvant capecitabine.^[13]
• Unresectable disease — biliary drainage (ESGE: uncovered SEMS for palliative malignant hilar obstruction), systemic chemotherapy (gemcitabine plus cisplatin, ABC-02 median OS 11.7 versus 8.1 months), and selective radiotherapy.^[7][13]

The rarer causes that still come up

Mirizzi syndrome is an impacted gallstone in Hartmann's pouch or the cystic duct compressing the common hepatic duct from outside, producing obstructive jaundice without a true CBD stone. Type I is external compression; types II to IV involve a cholecystocholedochal fistula eroding into the duct. MRCP shows the level; cholecystectomy with careful dissection — often subtotal to avoid iatrogenic CBD injury — is the treatment, and a Csendes type II or higher may need cholecystojejunostomy or biliary-enteric reconstruction.^[4]

Biliary atresia is the neonatal surgical cause of conjugated jaundice — pale stools, dark urine, and progressive conjugated hyperbilirubinaemia in early infancy. Kasai portoenterostomy and, when needed, later transplantation are the surgical pathway; quote the paediatric protocol rather than a memorised day-of-life cut-off.^[1]

Post-cholecystectomy jaundice within days of the operation means one of three things — a retained CBD stone (commonest), an iatrogenic CBD injury (clip, transection, thermal stricture), or a bile leak with biloma compressing the duct. Urgent MRCP, ERCP, and re-exploration in a tertiary HPB unit is the algorithm; early referral for primary repair at the index operation outperforms delayed reconstruction.^[1][7]

Parasitic obstruction. Ascaris lumbricoides worms migrate up the papilla into the bile duct, presenting with biliary colic, cholangitis, obstructive jaundice, or pancreatitis. A prospective series of 98 patients started everyone on oral albendazole 400 mg plus analgesics: about a quarter (23.5 per cent) cleared with medical management alone, while presentation with obstructive jaundice or cholangitis predicted failure — those patients went on to ERCP, which achieved biliary clearance in 86.7 per cent. Liver flukes (Opisthorchis, Clonorchis) drive chronic biliary inflammation and cholangiocarcinoma in endemic regions; the anthelmintic praziquantel decreases the risk of cholangiocarcinoma from liver flukes, though reinfection is common.^[25][13]

Ampullary and periampullary carcinoma (ampulla of Vater, distal CBD, second part of duodenum) shares the Whipple approach with pancreatic head cancer but typically obstructs earlier and presents at smaller size. Distal cholangiocarcinoma post-resection survival in Brindley ranges 20 to 40 per cent depending on extent — do not quote a separate unsourced ampullary 5-year figure.^[1]

Benign biliary stricture most often follows cholecystectomy (clip misplacement, thermal injury, ischaemia), with chronic pancreatitis and primary sclerosing cholangitis behind it. ESGE recommends temporary insertion of multiple plastic stents or of a fully covered SEMS for benign biliary strictures. Surgical Roux-en-Y hepaticojejunostomy is reserved for endoscopic failure, complex hilar strictures, or low CBD injuries.^[7]

ERCP complications and how to dodge them

ERCP is therapeutic, and it bites — name the complications and their measured rates. The Cotton consensus (1991) put overall complications of sphincterotomy at about 10 per cent, with 2 to 3 per cent needing prolonged hospitalisation; the largest prospective series (2347 patients, 17 centres) put hard numbers on the individual events.^[2][19]

^{[19] [2]}

Risk-stratify every ERCP. In the prospective multicentre series the risk of complications was highest when the indication was suspected sphincter of Oddi dysfunction (21.7 per cent) and lowest for stone extraction soon after laparoscopic cholecystectomy (4.9 per cent); independent predictors were suspected sphincter of Oddi dysfunction, cirrhosis, difficult cannulation, precut sphincterotomy, and combined percutaneous-endoscopic procedures — not age or bile-duct diameter. Volume matters too: endoscopists doing more than one sphincterotomy per week had fewer complications (8.4 versus 11.1 per cent).^[19]

The prophylaxis with trial evidence: in a multicentre randomised trial of 602 high-risk patients, a single dose of rectal indomethacin immediately after ERCP cut post-ERCP pancreatitis from 16.9 to 9.2 per cent (moderate-to-severe disease halved, 8.8 to 4.4 per cent).^[20] The ESGE therefore recommends routine rectal diclofenac or indomethacin 100 mg immediately before or after ERCP in all patients without contraindication, plus a 5-Fr prophylactic pancreatic stent strongly considered in high-risk cases; note that Freeman's 2016 review tempers the rectal-NSAID enthusiasm in unselected cohorts and holds pancreatic stent placement the most proven and reliable method.^[21][15]

Pitfalls, prognosis, and special populations

The recurring pitfalls every candidate must name. Missing pancreatic cancer by attributing a Courvoisier-positive gallbladder to stones. Performing ERCP before MRCP in an intermediate-probability patient — wasteful, and it exposes the patient to pancreatitis when MRCP would have excluded obstruction. Operating with a raised INR — weeks of obstruction mean vitamin K deficiency; check and correct first. Failing to drain an obstructed, infected system — antibiotics alone are insufficient in cholangitis; decompression is the definitive therapy. And misreading CA 19-9 in cholestasis or in a Lewis-negative patient.^[1]

Disease-related complications include ascending cholangitis and septic shock, secondary biliary cirrhosis within months of unrelieved obstruction, hepatorenal syndrome from biliary sepsis, coagulopathy and bleeding, fat-soluble vitamin deficiency, and renal failure from bilirubin nephropathy or sepsis-associated acute kidney injury.^[1]

Prognosis by cause

Prognosis is wholly determined by cause — the table is the answer to every prognostic stem.^[1]

^[1]

Disposition: most obstructed patients need admission for imaging, drainage, or surgery. Ascending cholangitis is an immediate surgical admission with ICU input for grade III. Pancreatic and cholangiocarcinoma pathways belong in the multidisciplinary HPB tumour board. Discharge is appropriate once jaundice is relieved, cholangitis treated, coagulopathy corrected, and a clear definitive plan communicated to patient and general practitioner.^[1]

Special populations

• Elderly patients carry a higher probability of malignancy at any level of obstruction — always image with contrast CT and keep a low threshold for MRCP. Atypical presentations are common: confusion without fever may be the only sign of cholangitis. Reserve major resection (Whipple) for the physiologically fit over 80; frailty scoring (CRS, mFI) guides shared decision-making.^[1]
• Pregnancy — obstructive jaundice is rare, mostly choledocholithiasis; intrahepatic cholestasis of pregnancy is the principal differential (third trimester, pruritus, raised bile acids, normal GGT). ERCP is feasible with lead shielding, left lateral position, and minimal fluoroscopy; sphincterotomy and stone extraction are safe in the second and third trimester. Defer cholecystectomy to the post-partum period after stone clearance in the asymptomatic; recurrent biliary colic or pancreatitis warrants same-admission cholecystectomy in the second trimester.^[1]
• Cirrhosis and chronic liver disease — obstruction may be masked by parenchymal dysfunction, but the GGT and ALP pattern still discriminates. Cirrhosis complicates extended hepatectomy (Klatskin resection); portal hypertension also raises ERCP bleeding risk — quantify operative risk with the local HPB MDT rather than a memorised MELD cut-off.^[1]
• Post-cholecystectomy — always consider a retained or recurrent CBD stone or a post-surgical stricture; MRCP is the diagnostic test of choice.^[1]
• Immunocompromised (HIV, post-transplant) — consider AIDS cholangiopathy (cryptosporidium, CMV, microsporidium causing papillary stenosis and sclerosing-cholangitis-like changes) and drug-induced cholestasis from antiretrovirals and immunosuppressants (azathioprine, ciclosporin, tacrolimus).^[1]
• Anticoagulated patients — bridge to heparin or withhold warfarin before ERCP with sphincterotomy; check the INR immediately pre-procedure. Direct oral anticoagulants are omitted per local endoscopy-anticoagulation protocol and resumed once haemostasis is secured.^[1]

Guidelines, regions, and where the evidence is weak

ESGE 2018 biliary stenting (Dumonceau) recommends SEMS insertion for palliative drainage of extrahepatic malignant biliary obstruction, 10-mm SEMS when preoperative drainage is required, and against uncovered SEMS if the etiology is unconfirmed. TG18 deleted prophylactic antimicrobials for elective ERCP.^[7]

Tokyo Guidelines 2018 (TG18) standardised diagnosis, severity grading, and management bundles. Gomi lists empirical agents by class and by TG18 severity grade I–III, subcategorised by community- versus healthcare-associated setting, with early de-escalation once isolates return. Prophylactic antimicrobials for elective ERCP are no longer recommended.^[8][9][10]

Where the evidence is weak: preoperative biliary drainage in resectable pancreatic cancer is debated in the era of neoadjuvant FOLFIRINOX — most centres now stent through the 2 to 3 months of neoadjuvant therapy, but the Dutch trial's caution against routine stenting still applies to patients going straight to surgery. Covered versus uncovered SEMS for hilar cholangiocarcinoma, antibiotic prophylaxis in fully drained ERCP, and adjuvant therapy for resected cholangiocarcinoma remain areas of active investigation.^[5][7]

The mantra, and the mnemonics

^{[1] [8]}

The mantra: Dark urine and pale stools mean obstruction; a palpable gallbladder means cancer; fever and right-upper-quadrant pain mean drain it now.^[1][8]

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)ShowHide

The 68-year-old with three weeks of painless progressive jaundice, weight loss, and a smooth non-tender ballotable right-upper-quadrant mass. What is the diagnosis, and what are the next two investigations? Model: This is Courvoisier-positive obstructive jaundice — pancreatic head cancer until proven otherwise. A palpable, non-tender, distended gallbladder in a jaundiced patient is malignancy, not stones; the law is statistical but the working diagnosis is cancer. The next two investigations are a contrast-enhanced CT with a pancreatic protocol for staging and resectability (vascular encasement of the superior mesenteric artery or coeliac axis, metastases) and an MRCP to define the level and length of the biliary obstruction. Do not attribute the gallbladder to stones, and do not send him home for clinic review.^[1]

Stem 2 — the woman in rigors (answer)ShowHide

A 54-year-old arrives febrile at 39.2 degrees Celsius with rigors, jaundice, right-upper-quadrant pain, and a blood pressure of 88/52. What is the diagnosis, and what do you do in the first hour and the next 24 to 48 hours? Model: This is Charcot's triad with hypotension — Reynolds' pentad, the highest-severity band of ascending cholangitis. First hour: run the TG18 bundle — diagnostic process, severity assessment, transfer if necessary, and therapeutic approach at each time point — which means empirical IV antimicrobials chosen by severity grade and healthcare- versus community-acquired setting, with ICU input for the shock, and early de-escalation once isolates return. Check and correct coagulopathy. Definitive care is biliary drainage — the big-data validation showed 30-day mortality is significantly higher at higher severity grades and significantly lower in Grade II patients drained early or urgently; antibiotics alone will not clear infected bile under pressure. Percutaneous or surgical drainage are the fallback if ERCP fails.^[8][9][10]

Stem 3 — the high CA 19-9 trap (answer)ShowHide

A jaundiced 60-year-old has a CA 19-9 of 800 units per millilitre. Give two reasons not to call this pancreatic cancer yet. Model: First, CA 19-9 rises in benign biliary disease: in a prospective series of 70 patients with choledocholithiasis, 46 per cent had elevated CA 19-9 and 11 per cent exceeded 1000 units per millilitre — levels correlated with ALP, GGT and bilirubin, every cholangitis patient was elevated (100 versus 41 per cent), and values normalised within 1 to 28 days of stone extraction. A stone with cholangitis can push it to 800. Second, subjects with the Lewis (a-b-) genotype give false-negative results — a normal value excludes nothing. The marker is unreliable in both directions: interpret it only alongside imaging.^[22][23]

References28ShowHide

1. [1]Elmunzer BJ, Maranki JL, Gómez V, et al. ACG Clinical Guideline: Diagnosis and Management of Biliary Strictures Am J Gastroenterol, 2023.PMID 36863037
2. [2]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus Gastrointest Endosc, 1991.PMID 2070995
3. [3]Garrow D, Miller S, Sinha D, et al. Endoscopic ultrasound: a meta-analysis of test performance in suspected biliary obstruction Clin Gastroenterol Hepatol, 2007.PMID 17478348
4. [4]Tazuma S, Unno M, Igarashi Y, et al. Evidence-based clinical practice guidelines for cholelithiasis 2016 J Gastroenterol, 2017.PMID 27942871
5. [5]van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas N Engl J Med, 2010.PMID 20071702
6. [6]Buxbaum JL, Abbas Fehmi SM, Sultan S, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis Gastrointest Endosc, 2019.PMID 30979521
7. [7]Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017 Endoscopy, 2018.PMID 30086596
8. [8]Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos) J Hepatobiliary Pancreat Sci, 2018.PMID 29032610
9. [9]Gomi H, Solomkin JS, Takada T, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis J Hepatobiliary Pancreat Sci, 2018.PMID 29090866
10. [10]Mayumi T, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis J Hepatobiliary Pancreat Sci, 2018.PMID 29090868
11. [11]Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med, 2011.PMID 21561347
12. [12]Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet, 2017.PMID 28129987
13. [13]Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma Nat Rev Dis Primers, 2021.PMID 34504109
14. [14]Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement HPB (Oxford), 2015.PMID 26172136
15. [15]Freeman ML Preventing Post-ERCP Pancreatitis: Update 2016 Curr Treat Options Gastroenterol, 2016.PMID 27349659
16. [16]de Graaf N, Emmen AAMH, Ramera M, et al. Minimally Invasive versus Open Pancreatoduodenectomy for Resectable Neoplasms NEJM Evid, 2025.PMID 41288428
17. [17]Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis Am J Gastroenterol, 2005.PMID 15667485
18. [18]Mohamed MFH, Elfert K, Wadhavkar N, et al. Choledocholithiasis Can Present with Marked Transaminases Elevation: Systematic Review and Meta-Analysis Dig Dis Sci, 2023.PMID 37269372
19. [19]Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy N Engl J Med, 1996.PMID 8782497
20. [20]Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis N Engl J Med, 2012.PMID 22494121
21. [21]Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014 Endoscopy, 2014.PMID 25148137
22. [22]Doğan ÜB, Gümürdülü Y, Gölge N, et al. Relationship of CA 19-9 with choledocholithiasis and cholangitis Turk J Gastroenterol, 2011.PMID 21796554
23. [23]Scarà S, Bottoni P, Scatena R CA 19-9: Biochemical and Clinical Aspects Adv Exp Med Biol, 2015.PMID 26530370
24. [24]Beuers U, Wolters F, Oude Elferink RPJ Mechanisms of pruritus in cholestasis: understanding and treating the itch Nat Rev Gastroenterol Hepatol, 2023.PMID 36307649
25. [25]Patra PS, Das A, Ahmed SKM, et al. Treatment response and long-term outcomes in biliary ascariasis: A prospective study Arab J Gastroenterol, 2021.PMID 33752976
26. [26]Ruiz MA, Saab S, Rickman LS The clinical detection of scleral icterus: observations of multiple examiners Mil Med, 1997.PMID 9271910
27. [27]Degrassi I, Leonardi I, Di Profio E, et al. Fat-Soluble Vitamins Deficiency in Pediatric Cholestasis: A Scoping Review Nutrients, 2023.PMID 37299454
28. [28]Sullivan JI, Rockey DC Diagnosis and evaluation of hyperbilirubinemia Curr Opin Gastroenterol, 2017.PMID 28333690